LAD, NIAID, NIH, Bethesda, MD. RATIONALE: Current U.S. federal law does not require food manufacturers to declare sesame in their products, although sesame is considered a major allergen in other parts of the world. The exact prevalence of sesame allergy in the U.S. is unknown.The diagnosis is challenging as there are no identified sesame-specific IgE or skin prick test thresholds that predict clinical reactivity. METHODS: 72 consecutive patients (median age 9.5: IQR 9) with IgEmediated food allergy were assessed for clinical reactivity to sesame and peanut/tree nuts. Sesame allergy was defined as an immediate hypersensitivity to sesame at home or via clinic food challenge, and tolerance as the ability to ingest concentrated sesame (tahini) with no symptoms. Sesamespecific and total IgE were measured by ImmunoCAP. RESULTS: Twelve (16.6%) of 72 patients with food allergy were allergic to sesame and 60 were tolerant. Sesame sIgE levels were higher in the allergic group (median 26.40 kU A /L versus 1.96 kU A /L, respectively; p5.000339). Of those allergic to sesame, 9/12 (75%) were also allergic to peanut or any tree nut, compared to 26 (43.3%) in the tolerant group. Adjustment for total serum IgE did not improve the ability of sesame sIgE to predict allergy. CONCLUSIONS: Sesame allergy is common among children with IgEmediated food allergy in this cohort, and often co-occurs with peanut/tree nut allergy. Further investigation will examine age of sesame introduction into the diet, ability of sesame allergic patients to tolerate seeds/oil, and the effect of eczema and elevated total IgE on modifying the utility of sesame IgE in predicting allergy. The prevalence of cashew allergy has increased in recent years. To develop an epicutaneous immunotherapy (EPIT) treatment to cashew allergy, the availability of an anaphylaxis animal model for preclinical studies is a prerequisite. METHODS: Mice (N 5 8) were sensitized to cashew using an oral or cutaneous sensitization protocol. Following sensitization, mice were challenged orally with cashew extracts. Anaphylactic reactions were assessed by measuring body temperature, clinical symptoms and mucosal mast cell proteases (mMCP) concentration in serum. To further evaluate the relevance of our model for the evaluation of EPIT, a second set of mice were challenged 8 weeks after the end of the sensitization to ensure the sustainability of the anaphylactic response. RESULTS: Mice sensitized to cashew developed a significant increase in serum cashew-specific IgE (mean IgE titer of 1.3 6 0.6 mg/mL and 4.5 6 0.6 mg/mL for cutaneous and oral routes, respectively, compared to 0.0 6 0.0 for na€ ıve mice, p<0.001). Upon challenge, mice experienced a sharp drop in body temperature (mean percentage of temperature drop 35 min after challenge 5 18.3 6 3.1 % and 15.7 6 1.8 % for cutaneous and oral routes, respectively, compared to 0.3 6 1.3 % for na€ ıve mice, p<0.001) associated with severe clinical symptoms and a significant increase of mMCP-1/7 levels in serum. Similar results were obtained in the mice challenged 8 weeks after the end of sensitization. CONCLUSIONS: A robust mouse model of cashew anaphylaxis was developed to evaluate the efficacy of EPIT for desensitization to cashew allergy.
The prevalence of cashew allergy has increased in recent years. To develop an epicutaneous immunotherapy (EPIT) treatment to cashew allergy, the availability of an anaphylaxis animal model for preclinical studies is a prerequisite. METHODS: Mice (N 5 8) were sensitized to cashew using an oral or cutaneous sensitization protocol. Following sensitization, mice were challenged orally with cashew extracts. Anaphylactic reactions were assessed by measuring body temperature, clinical symptoms and mucosal mast cell proteases (mMCP) concentration in serum. To further evaluate the relevance of our model for the evaluation of EPIT, a second set of mice were challenged 8 weeks after the end of the sensitization to ensure the sustainability of the anaphylactic response. RESULTS: Mice sensitized to cashew developed a significant increase in serum cashew-specific IgE (mean IgE titer of 1.3 6 0.6 mg/mL and 4.5 6 0.6 mg/mL for cutaneous and oral routes, respectively, compared to 0.0 6 0.0 for na€ ıve mice, p<0.001). Upon challenge, mice experienced a sharp drop in body temperature (mean percentage of temperature drop 35 min after challenge 5 18.3 6 3.1 % and 15.7 6 1.8 % for cutaneous and oral routes, respectively, compared to 0.3 6 1.3 % for na€ ıve mice, p<0.001) associated with severe clinical symptoms and a significant increase of mMCP-1/7 levels in serum. Similar results were obtained in the mice challenged 8 weeks after the end of sensitization. CONCLUSIONS: A robust mouse model of cashew anaphylaxis was developed to evaluate the efficacy of EPIT for desensitization to cashew allergy.
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Long term follow up of egg tolerance in egg allergic patients challenged to baked egg. In this study, we follow-up patients who tolerated baked egg oral food challenges (BE-OFC) and characterize their tolerance to nonbaked, regular lightly cooked egg, e.g., scrambled egg or French toast. METHODS: We performed retrospective chart reviews of egg allergic patients who visited Mount Sinai pediatric allergy clinic from January 2008 to December 2017 and passed BE-OFCs to muffin baked with egg. We characterized their progression to non-baked egg. RESULTS: Among 50 patients, median age of 4.9 years (IQR: 3.1-9), 62% male at the time of the BE-OFC. Forty-two patients (84%) continued to ingest BE products by the first follow up appointment (median: 9 months; IQR: 6-16) and subsequently 1 year after passing BE-OFC. Eight patients (17%) discontinued BE within 1 year, due to symptoms with ingestion at home (62.5%) or fear of home introduction (37.5%). Symptoms reported by patients with home introduction were mostly mild, such as oral itching (50%), hives (25%) or abdominal pain (37.5%), however there was one report of anaphylaxis. Sixty-three percent of patients reporting symptoms with home introduction discontinued BE. Thirty-five patients (83%) eating BE ultimately progressed to tolerating non-baked egg over a median of 13.5 months (IQR: 9-23). CONCLUSIONS: The majority of subjects passing BE-OFC added BE to regular diet at home. Our data confirms previous findings that tolerance to non-baked egg is achieved in the majority of patients ingesting BE. Tolerance is also sustained long-term in patients who ingested baked egg products.
